New drug tested in fight against deadly sepsis kidney damage
NCT ID NCT05507437
Summary
This study tested a new drug called TIN816 in 20 hospitalized adults with kidney injury caused by a severe bloodstream infection (sepsis). The main goal was to see how the drug moves through the body and to check its safety. Patients in intensive care received either TIN816 or a placebo, and researchers tracked them for 90 days.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY DUE TO SEPSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Genk, 3600, Belgium
-
Novartis Investigative Site
Ottignies, 1340, Belgium
-
Novartis Investigative Site
Strasbourg, 67091, France
-
Novartis Investigative Site
Toulouse, 31054, France
-
Novartis Investigative Site
Kiel, 24105, Germany
-
Novartis Investigative Site
Debrecen, 4032, Hungary
-
Novartis Investigative Site
Valencia, 46026, Spain
Conditions
Explore the condition pages connected to this study.